High-titer heterologous protein production using engineered pichia

Overview

Shreenika specializes in biomanufacturing using engineered Pichia strains for high-titer production of enzymes and proteins. Our platform leverages advanced genetic engineering techniques, including CRISPR and recombinase systems, to enhance protein expression stability even under stress. This technology is particularly suited for biologics production, offering an antibiotic-free system with proven high yields, making it ideal for diverse industrial applications.

Technical specifications

• Gene modification tools: Utilizes CRISPR, base editors, and recombinase systems to enhance genetic stability and reduce mutation rates.
• Inducible systems: Prevents mutations before induction, ensuring stable cell lineages.
• Multicopy integration: Provides redundancy against mutational escape, demonstrated by manufacturing glycosidase at 10 g/L titers.
• Screening and optimization: Employs 96 deep-well plate screening and DOE experiments for strain selection and optimization.
• Scalability: Capable of manufacturing at industry-lowest costs up to 100 KL scale.

Technology readiness level

This technology is at TRL 6, having been validated in relevant environments. It is prepared for further scale-up and commercial deployment, with planned validation to 5L scale before larger production runs.